Summary: Delve Bio has partnered with Broad Clinical Labs to accelerate the commercialization and accessibility of metagenomic next-generation sequencing (mNGS) for diagnosing neurological infections like meningitis and encephalitis.
Takeaways:
- Delve Bio’s mNGS platform provides rapid, hypothesis-free diagnosis for neurological infections by sequencing all nucleic acids in a sample to identify pathogens.
- The partnership with Broad Clinical Labs enhances Delve Bio’s capacity to scale its diagnostic offerings, delivering results in just two days.
- Delve Bio’s flagship test, Delve Detect, is expected to be more widely available by fall, offering clinicians a powerful tool for diagnosing complex infections
Delve Bio, a provider in metagenomic next generation sequencing (mNGS) for infectious diseases, and Broad Clinical Labs (BCL), a genome sequencing and testing laboratory, announced a partnership that will bring together experts in neurology, infectious disease, and clinical genomics to rapidly scale up access to metagenomics for patients with neurological infections.
“Diagnosing infectious diseases often becomes a diagnostic odyssey, particularly in cases of meningitis and encephalitis. Delve Bio is working to bring infectious disease diagnostics into the genomics era, enabling patients with undiagnosed neurological infections to get a definitive diagnosis quickly,” says Brad Murray, CEO of Delve Bio. “We’re proud to partner with Broad Clinical Labs to bring high-quality laboratory operations and sequencing at-scale to Delve’s customers.”
Diagnosing Neurological Infections
Delve Bio’s mNGS platform provides a hypothesis-free approach to diagnosing neurological infections by sequencing all nucleic acids in a sample and identifying bacteria, fungi, parasites, and viruses that could be causing the infection. Through its partnership with Broad Clinical Labs, Delve Bio will gain access to the expertise, scalability, and efficiency of Broad Clinical Labs, accelerating the company’s commercialization efforts which include clinical operations that deliver results in two days.
Broad Clinical Labs has a history of providing high quality genome sequencing and analysis at scale across a range of biomedical applications.
“Metagenomic sequencing holds tremendous promise to improve diagnosis in infectious diseases. We have built deep expertise in clinical testing for infectious diseases at scale, including our experience performing more than 37.5 million tests during the COVID pandemic,” says Niall J. Lennon, PhD, chair and chief scientific officer of Broad Clinical Labs. “We are proud to work with Delve Bio to increase access to this important diagnostic assay.”
Delve Bio was founded by Drs. Charles Chiu, Joe DeRisi, Michael Wilson, and the Broad Institute’s Matthew Meyerson and Pardis Sabeti – world leaders in genomics and infectious disease. The company holds the exclusive license from the University of California San Francisco (UCSF) for its clinically-validated, mNGS technology widely used by clinicians to solve cases of meningitis and encephalitis. The company’s flagship cerebrospinal fluid pathogen identification test, Delve Detect, is expected to become more broadly available this fall.
